Former Algeta CEO named Advancell’s chair-elect

Andrew Kay has been named a director and chair-elect of Sydney-based radiopharma company Advancell Pty. Ltd., succeeding Bill Ferris. Kay was CEO of Algeta ASA, a Norwegian oncology company, until its $2.9 billion acquisition by Bayer AG (Xetra:BAYN) a decade ago. At Algeta, he helped drive the development and commercialization of the first approved α-emitter, Xofigo. Kay is also chair of U.K. biotech Nerre Therapeutics Ltd.

Ona Therapeutics S.L. named Antoine Yver chair as the Barcelona-based antibody-drug conjugate company’s lead ADC moves closer to the clinic. Yver was chair of development at Centessa Pharmaceuticals plc (NASDAQ:CNTA) and, before that, global head of oncology R&D at Daiichi Sankyo Co. Ltd...